450 related articles for article (PubMed ID: 26690587)
1. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H; Okamoto I
Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
[TBL] [Abstract][Full Text] [Related]
2. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
Ahn SY; Kim J; Kim MA; Choi J; Kim WH
Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
[TBL] [Abstract][Full Text] [Related]
3. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
5. c-Met targeting in advanced gastric cancer: An open challenge.
Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
[TBL] [Abstract][Full Text] [Related]
6. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors.
Torti D; Sassi F; Galimi F; Gastaldi S; Perera T; Comoglio PM; Trusolino L; Bertotti A
Int J Cancer; 2012 Mar; 130(6):1357-66. PubMed ID: 21500189
[TBL] [Abstract][Full Text] [Related]
7. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
Wang J; Goetsch L; Tucker L; Zhang Q; Gonzalez A; Vaidya KS; Oleksijew A; Boghaert E; Song M; Sokolova I; Pestova E; Anderson M; Pappano WN; Ansell P; Bhathena A; Naumovski L; Corvaia N; Reilly EB
BMC Cancer; 2016 Feb; 16():105. PubMed ID: 26879245
[TBL] [Abstract][Full Text] [Related]
8. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
Joo MK; Park JJ; Chun HJ
World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
[TBL] [Abstract][Full Text] [Related]
9. cMET as a potential therapeutic target in gastric cancer (Review).
Teng L; Lu J
Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
11. Biomarker development in MET-targeted therapy.
Zhang Y; Du Z; Zhang M
Oncotarget; 2016 Jun; 7(24):37370-37389. PubMed ID: 27013592
[TBL] [Abstract][Full Text] [Related]
12. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
13. Role of c-mesenchymal-epithelial transition pathway in gastric cancer.
Fioroni I; Dell'Aquila E; Pantano F; Intagliata S; Caricato M; Vincenzi B; Coppola R; Santini D; Tonini G
Expert Opin Pharmacother; 2015 Jun; 16(8):1195-207. PubMed ID: 25881479
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
15. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
Bradley CA; Salto-Tellez M; Laurent-Puig P; Bardelli A; Rolfo C; Tabernero J; Khawaja HA; Lawler M; Johnston PG; Van Schaeybroeck S;
Nat Rev Clin Oncol; 2017 Sep; 14(9):562-576. PubMed ID: 28374784
[TBL] [Abstract][Full Text] [Related]
16. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
18. Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach.
Lee J; Tran P; Klempner SJ
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e35-44. PubMed ID: 26880063
[TBL] [Abstract][Full Text] [Related]
19. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.
Hack SP; Bruey JM; Koeppen H
Oncotarget; 2014 May; 5(10):2866-80. PubMed ID: 24930887
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]